Instruction 1(b)

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL						
OMB Number:	3235-02					

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

87 Estimated average burden hours per response: 0.5

5. Relationship of Reporting Person(s) to Issuer 2. Issuer Name and Ticker or Trading Symbol 1. Name and Address of Reporting Person* (Check all applicable) VERTEX PHARMACEUTICALS INC / **BOGER JOSHUA S** MA [VRTX] Officer (give title Other (specify X below) below) (Middle) (Last) (First) Chairman & CEO 3. Date of Earliest Transaction (Month/Day/Year) C/O VERTEX PHARMACEUTICALS 05/18/2004 **INCORPORATED** 130 WAVERLY STREET 4. If Amendment, Date of Original Filed (Month/Day/Year) 6. Individual or Joint/Group Filing (Check Applicable Line) (Street) Form filed by One Reporting Person **CAMBRIDGE** 02139 MA Form filed by More than One Reporting (City) (State) (Zip)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned										
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)					5. Amount of Securities Beneficially Owned Following Reported	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	v	Amount	(A) or (D)	Price	Transaction(s) (Instr. 3 and 4)		(111341. 4)
Common Stock	05/18/2004		M		7,000	A	\$6	978,577	D	
Common Stock	05/18/2004		S ⁽¹⁾		7,000	D	\$8.4	971,577	D	
Common Stock								10,106	I	401(k)
Common Stock								207,500	I	shares in trust ⁽²⁾

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities) 1. Title of Derivative 6. Date Exercisable and 9. Number of 3. Transaction 3A. Deemed 5. Number 8. Price of 11. Nature Conversion Derivative of Indirect **Execution Date** Transaction Expiration Date Amount of derivative Ownership Security (Instr. 3) or Exercise Price of (Month/Day/Year) Code (Instr. Derivative (Month/Day/Year) Form: Direct (D) (Month/Day/Year) (Instr. 5) Beneficially 8) Underlying Ownership Securities Acquired (A) or Disposed Derivative **Derivative Security** Owned or Indirect (Instr. 4) Following Reported Security (Instr. 3 and 4) (I) (Instr. 4) of (D) (Instr. 3, 4 Transaction(s) (Instr. 4) and 5) Amount Number Date **Expiration** (D) Exercisable (A) Title Stock 05/18/2004 12/07/2004 7,000 1,555,223 03/08/1995(3) D

Explanation of Responses:

- 1. Transaction made pursuant to Dr. Boger's company approved trading plan established under Rule 10b5-1.
- 2. Shares held in trust for Dr. Boger's children. Dr. Boger disclaims beneficial ownership of such shares.
- 3. Right to buy under 1994 Stock and Option Plan, vesting in 20 equal quarterly installments from 12/8/1994.

Remarks:

Option

Kenneth S. Boger, Attorney-In-05/19/2004 **Fact**

** Signature of Reporting Person Date

Stock

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.